High Glucose-Induced Alterations in Subendothelial Matrix Perlecan Leads to Increased Monocyte Binding

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 24, Issue 5, 2004, Pages 858-863

  Vogl Willis, Catherine A ^a   Edwards, Iris J ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Diabetes; Endothelial cell; Hyperglycemia; Monocyte binding; Perlecan

Indexed keywords

GLUCOSE; METHIONINE; PERLECAN; PROTEOGLYCAN;

ARTICLE; AUTORADIOGRAPHY; CARDIOVASCULAR RISK; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; HYPERGLYCEMIA; LEUKOCYTE ADHERENCE; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUBENDOTHELIUM;

AGGRECANS; ANIMALS; AORTA; CATTLE; CELL ADHESION; CELLS, CULTURED; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; EXTRACELLULAR MATRIX; EXTRACELLULAR MATRIX PROTEINS; GLUCOSE; GLYCOSAMINOGLYCANS; HEPARAN SULFATE PROTEOGLYCANS; HUMANS; LECTINS, C-TYPE; MONOCYTES; PROTEOGLYCANS; SULFATES;

EID: 1642616525     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000126375.60073.74     Document Type: Article

References (43)

1. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16:434-444.
2. UK Prospective Diabetes Study (UKPDS) group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
3. Murdoch AD, Liu B, Schwarting R, Tuan RS, Iozzo RV. Widespread expression of perlecan proteoglycan in basement membranes and extracellular matrices of human tissues as detected by a novel monoclonal antibody against domain III and by in situ hybridization. J Histochem Cytochem. 1994;42:239-249.
4. Shimomura H, Spiro RG. Studies on macromolecular components of human glomerular basement membrane and alterations in diabetes: Decreased levels of heparan sulfate proteoglycan and laminin. Diabetes. 1987;36:374-381.
5. Wasty F, Alavi MZ, Moore S. Distribution of glycosaminoglycans in the intima of human aortas: changes in atherosclerosis and diabetes mellitus. Diabetologia. 1993;36:316-322.
6. Stevens RL, Colombo M, Gonzales JJ, Hollander W, Schmid K. The glycosaminoglycans of the human artery and their changes in atherosclerosis. J Clin Invest. 1976;58:470-481.
7. Gerrity RG. The role of the monocyte in atherogenesis. Am J Pathol. 1981; 103:181-190.
8. Pillarisetti S, Obunike JC, Goldberg IJ. Lysolecithin-induced alteration of subendothelial heparan sulfate proteoglycans increases monocyte binding to matrix. J Biol Chem. 1995;270:29760-29765.
9. Pillarisetti S, Klein MG, Goldberg IJ. Identification of a heparin-releasable lipoprotein lipase binding protein from endothelial cells. J Biol Chem. 1992; 267:16517-16522.
10. Pillarisetti S, Paka L, Obunike J, Berglund L, Goldberg IJ. Subendothelial retention of lipoprotein(a): evidence that reduced heparan sulfate promotes lipoprotein binding to subendothelial matrix. J Clin Invest. 1997;100: 867-874.
11. Edwards IJ, Wagner WD. Distinct synthetic and structural characteristics of proteoglycans produced by cultured artery smooth muscle cells of atherosclerosis-susceptible pigeons. J Biol Chem. 1988;263:9612-9620.
12. Oike Y, Kimata K, Shinomura T, Nakazawa K, Suzuki S. Structural analysis of chick-embryo cartilage proteoglycan by selective degradation with chondroitin lyases (chondroitinases) and endo-β-D-galactosidase (keratinase). Biochem J. 1980;191:193-207.
13. Vogl-Willis CA, and Edwards IJ. High glucose-induced structural changes in the heparan sulfate proteoglycan, perlecan, of cultured human aortic endothelial cells. Biochim Biophys Acta. 2004;in press.
14. Saku T, and Furthmayr H. Characterization of the major heparan sulfate proteoglycan secreted by bovine aortic endothelial cells in culture. J Biol Chem. 1989;264:3514-3523.
15. Muller WA and Randolph GJ. Migration of leukocytes across endothelium and beyond: molecules involved in the transmigration and fate of monocytes. J Leukoc Biol. 1999;66:698-704.
16. Randolph GJ, Furie MB. Mononuclear phagocytes egress from an in vitro model of the vascular wall by migrating across endothelium in the basal to apical direction: role of intercellular adhesion molecule 1 and the CD11/CD18 integrins. J Exp Med. 1996;183:451-462.
17. Brownlee M and Spiro RG. Biochemistry of the basement membrane in diabetes mellitus. Adv Exp Med Biol. 1979;124:141-156.
18. Ledbetter S, Copeland EJ, Noonan D, Vogeli G, Hassel JR. Altered steady-state mRNA levels of basement membrane proteins in diabetic mouse kidneys and thromboxane synthase inhibition. Diabetes. 1990;39:196-203.
19. Roy S, Sala R, Cagliero E, Lorenzi M. Overexpression of fibronectin induced by diabetes or high glucose: phenomenon with a memory. Proc Natl Acad Sci USA. 1990;87:404-408.
20. Wahab NA, Harper K, Mason RM. Expression of extracellular matrix molecules in human mesangial cells in response to prolonged hyperglycaemia. Biochem J. 1996;316:985-992.
21. Kim JA, Berliner JA, Natarajan RD, Nadler JL. Evidence that glucose increases monocyte binding to human aortic endothelial cells. Diabetes. 1994;43:1103-1107.
22. Fisher E, McLennan SV, Tada H, Heffernan S, Yue DK, Turtle JR. Interaction of ascorbic acid and glucose on production of collagen and proteoglycan by fibroblasts. Diabetes. 1991;40:371-376.
23. Luscinskas, FW, MI Cybulsky, JM Kiely, CS Peckins, VM Davis, and MA Gimbrone Jr. Cytokine-activated human endothelial monolayers support enhanced neutrophil transmigration via a mechanism involving both endothelial-leukocyte adhesion molecule-1 and intercellular adhesion molecule-1. J Immunol. 1991;146:1617-1625.
24. Hadcocks S, Richardson M, Winocour PD, Hatton MWC. Intimal alterations in rabbit aortas during the first 6 months of alloxan-induced diabetes. Arterioscler Thromb. 1991;11:517-529.
25. Tsao PS, Niebauer J, Buitrago R, Lin PS, Wang B, Cooke JP, Chen YI, Reaven GM. Interaction of diabetes and hypertension on determinants of endothelial adhesiveness. Arterioscler Thromb Vasc Biol. 1998; 18:947-953.
26. Takami S, Yamashita S, Kihara S, Kameda-Takemura K, Matsuzawa Y. High concentration of glucose induces the expression of intercellular adhesion molecule-1 in human umbilical vein endothelial cells. Atherosclerosis. 1998;138:35-41.
27. Wagner OF, Jilma B. Putative role of adhesion molecules in metabolic disorders. Horm Metab Res. 1997;29:627-630.
28. Blann AD, McCollum CN. Circulating endothelial cell/leukocyte adhesion molecules in atherosclerosis. Thromb Haemost. 1994;72:151-154.
29. Kanwar YS, Linker A, Farquhar MG. Increased permeability of the glomerular basement membrane to ferritin after removal of glycosaminoglycans (heparan sulfate) by enzyme digestion. J Cell Biol. 1980;86:688-693.
30. 125I-bovine serum albumin. Lab Invest. 1982;47:177-184.
31. Vernier RL, Steffes MW, Sisson-Ross S, and Mauer SM. Heparan sulfate proteoglycan in the glomerular basement membrane in type 1 diabetes mellitus. Kidney Int. 1992;41:1070-1080.
32. Tamsma JT, van den Born J, Bruijn JA, Assmann KJM, Weening JJ, Berden JHM, Wieslander J, Schrama E, Hermans J, Veerkamp JH, Lemkes HHPJ, van der Woude FJ. Expression of glomerular extracellular matrix components in human diabetic nephropathy: decrease of heparan sulphate in the glomerular basement membrane. Diabetologia. 1994;37:313-320.
33. van Det NF, Van den Born J, Tamsma JT, Verhagen N, Berden JHM, Bruijn JA, Daha MR, Van der Woude FJ. Effects of high glucose on the production of heparan sulfate proteoglycan by mesangial and epithelial cells. Kidney Int. 1996;49:1079-1089.
34. Dolan M, Horchar T, Rigatti B, Hassell JR. Identification of sites in domain I of perlecan that regulate heparan sulfate synthesis. J Biol Chem. 1997;272: 4316-4322.
35. Kato M, Koike Y, Ito Y, Suzuki S, Kimata K. Multiple forms of heparan sulfate proteoglycans in the Engelbreth-Holm-Swarm mouse tumor. J Biol Chem. 1997;262:7180-7188.
36. Klein DJ, Brown DM, Oegema TR, Brenchley PE, Anderson JC, Dickinson MAJ, Horigan EA, Hassell JR. Glomerular basement membrane proteoglycans are derived from a large precursor. J Cell Biol. 1988;106:963-970.
37. Couchman JR, Kapoor R, Sthanam M, Wu RR. Perlecan and basement membrane-chondroitin sulfate proteoglycan (Bamacan) are two basement membrane chondroitin/dermatan sulfate proteoglycans in the Engelbreth-Holm-Swarm tumor matrix. J Biol Chem 1996;271:9595-9602.
38. Danielson KG, Martinez-Hernandez A, Hassell JR, Iozzo RV. Establishment of a cell fine from the EHS tumor:biosynthesis of basement membrane constituents and characterization of a hybrid proteoglycan containing heparan and chondroitin sulfate chains. Matrix. 1992;12:22-35.
39. Kokenyesi R, Silbert JE. Formation of heparan sulfate or chondroitin/ dermatan sulfate on recombinant domain 1 of mouse perlecan expressed in chinese hamster ovary cells. Biochem Biophys Res Commun. 1995;211: 262-267.
40. Tapanadechopone P, Hassell JR, Rigatti B, Couchman JR. Localization of glycosaminoglycan substitution sites on domain V of mouse perlecan. Biochem Biophys Res Commun. 1999;265:680-690.
41. Wu C, Dedhar S. Integrin-linked kinase (ILK) and its interactors: a new paradigm for the coupling of extracellular matrix to actin cytoskeleton and signaling complexes. J Cell Mol. 2001;155:505-510.
42. Hansen PM, Chowdhury T, Deckert T, Hellgren A, Bain SC, Pociot F. Genetic variation of the heparan sulfate proteoglycan gene (perlecan gene): association with urinary albumin excretion in IDDM patients. Diabetes. 1997;46:1658-1659.
43. Cai H, Wang XL, Wilcken DEL. Genetic polymorphism of heparan sulfate proteoglycan (perlecan, HSPG2), lipid profiles and coronary artery disease in the Australian population. Atherosclerosis. 2000;148:125-129.